Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program. As of May 29, 2025, the company has repurchased a total of 5,842,629 ordinary fully paid securities, including 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, specializing in providing pathology services. The company focuses on delivering clinical laboratory services across Australia, catering to the needs of healthcare providers and patients.
Average Trading Volume: 952,808
Technical Sentiment Signal: Sell
Current Market Cap: A$575.4M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue